Chagas disease, leishmaniasis and sleeping sickness affect 20 million people worldwide and lead to more than 50,000 deaths annually 1 . The diseases are caused by infection with the kinetoplastid parasites Trypanosoma cruzi, Leishmania spp. and Trypanosoma brucei spp., respectively. These parasites have similar biology and genomic sequence, suggesting that all three diseases could be cured with drugs that modulate the activity of a conserved parasite target 2 . However, no such molecular targets or broad spectrum drugs have been identified to date. Here we describe a selective inhibitor of the kinetoplastid proteasome (GNF6702) with unprecedented in vivo efficacy, which cleared parasites from mice in all three models of infection. GNF6702 inhibits the kinetoplastid proteasome through a non-competitive mechanism, does not inhibit the mammalian proteasome or growth of mammalian cells, and is well-tolerated in mice. Our data provide genetic and chemical validation of the parasite proteasome as a promising therapeutic target for treatment of kinetoplastid infections, and underscore the possibility of developing a single class of drugs for these neglected diseases.
with respect to growth inhibition of mammalian cells. An azabenzoxazole, GNF5343, was identified as a hit in the L. donovani and T. brucei screens. Although GNF5343 was not identified in the T. cruzi screen, we noted potent anti-T. cruzi activity of this compound in secondary assays.
Optimization of GNF5343 involved the design and synthesis of ~3,000 compounds, and focused on improving bioavailability and potency on inhibition of L. donovani growth within macrophages ( Fig. 1) . A critical modification involved replacement of the azabenzoxazole centre with C6-substituted imidazo-and triazolopyrimidine cores, which yielded compounds up to 20-fold more potent on intra-macrophage L. donovani (for example, GNF2636). Replacement of the furan group with a dimethyloxazole ring reduced the risk of toxicity associated with the furan moiety, and replacement of the chlorophenyl group with a fluorophenyl improved selectivity over mammalian cell growth inhibition (for example, GNF3849). These changes also resulted in low clearance and acceptable bioavailability. Further substitutions at the core C6 position led to GNF6702 and a 400-fold increase in intra-macrophage L. donovani potency compared to GNF5343.
Leishmania donovani parasites cause a majority of visceral leishmaniasis (VL) cases in East Africa and India 9 . In mice infected with L. donovani 10 , oral dosing with GNF6702 effected a more pronounced reduction in liver parasite burden than miltefosine, the only oral anti-leishmanial drug available in clinical practice 5 (Fig. 2a ). The miltefosine regimen for VL efficacy studies was chosen to approximate the drug plasma concentration of the clinical regimen 11 . We noted a greater than three-log reduction in parasite load after 1 Genomics Institute of the Novartis Research Foundation, 10675 John Jay Hopkins Drive, San Diego, California 92121, USA. 2 Wellcome Trust Centre for Molecular Parasitology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK. 3 Centre for Immunology and Infection, Department of Biology, University of York, Wentworth Way, Heslington, York YO10 5DD, UK. 4 Department of Medicine, University of Washington, Seattle, Washington 98109, USA. 5 Novartis Institute for Tropical Diseases, 10 Biopolis Road, Singapore 138670. *These authors contributed equally to this work. T. cruzi, amastigotes proliferating in 3T3 fibroblast cells; macrophage, mouse primary peritoneal macrophages; EC 50 and CC 50 , half-maximum growth-inhibition concentration; F, oral bioavailability in mouse after administering single compound dose (20 mg kg −1 ) as a suspension; CL, plasma clearance in mouse after single i.v. bolus dose (5 mg kg −1 ); ND, not determined; all EC 50 and CC 50 values correspond to means ± s.e.m. (n = 4 technical replicates). eight-day treatment with 10 mg kg −1 of GNF6702 twice-daily with the free concentration of GNF6702 (fraction unbound in plasma = 0.063) staying above the L. donovani EC 99 value (the concentration inhibiting 99% of intra-macrophage parasite growth in vitro) for the duration of the dosing period (Extended Data Fig. 1a ). Characterization of efficacy of ten analogues in the series at various doses revealed a significant correlation (r 2 = 0.89, P < 0.01) between (i) the ratio of mean free plasma compound concentration to the L. donovani EC 90 value and (ii) reduction of the liver parasite burden. We found that 90% parasite burden reduction in the mouse model was achieved when the mean free compound plasma concentration during treatment equalled a 0.94-fold multiple of the L. donovani EC 90 value (Fig. 2b) .
Cutaneous leishmaniasis (CL) affects about a million people per year, causing skin lesions that can resolve into scar tissue 12 . In parts of the Middle East, CL has reached epidemic proportions 13 . After footpad infection of BALB/c mice with the dermatotropic L. major strain 14, 15 , treatment with GNF6702 at 10 mg kg −1 twice-daily caused a fivefold decrease in footpad parasite burden and a reduction in footpad swelling (Fig. 2c ). Both 3 mg kg −1 and 10 mg kg −1 twice-daily regimens of GNF6702 were superior to 30 mg kg −1 once-daily miltefosine regimen (P < 0.01), which translates into an approximately twofold higher miltefosine plasma concentration in mice than observed in clinical dosing 11 .
We further tested if GNF6702 can cure additional kinetoplastid parasite infections. An estimated 25% of the 8 million people infected with T. cruzi will develop chronic Chagas disease, manifesting as cardiac or intestinal dysfunction 16, 17 . Benznidazole is broadly used for treatment of acute and indeterminate stages of Chagas disease in Latin America 18, 19 . However, benznidazole has side effects that frequently lead to treatment interruption 18, [20] [21] [22] and a better tolerated drug is needed. To model treatment in the indeterminate disease stage, we infected mice with T. cruzi parasites and began treatment 35 days after infection, when the immune system of the mice had controlled parasite burden 23 . We increased the parasite detection sensitivity by immunosuppressing the mice after 20 days of treatment 23,24 . In this model, GNF6702 dosed twice-daily at 10 mg kg −1 matched the efficacy of benznidazole at 100 mg kg −1 once-daily; all but one of the treated mice had no detectable parasites in blood, colon or heart tissue, even after 4 weeks of immunosuppression ( Fig. 2d ).
Finally, we tested GNF6702 in a mouse model of stage II sleeping sickness (human African trypanosomiasis (HAT)) 25 . Mortality of stage II HAT is caused by infection of the CNS and, in this mouse model, luciferase-expressing T. brucei parasites establish a CNS infection by day 21 post-infection. GNF6702 was administered at 100 mg kg −1 oncedaily to account for low exposure in the brain relative to the plasma (~10%, Extended Data Fig. 1b ). Diminazene aceturate, a stage I drug that poorly crosses the blood-brain barrier, effected apparent clearance of parasites from the blood after a single dose, but did not prevent parasite recrudescence 21 days later. By contrast, treatment with GNF6702 for seven days caused a sustained clearance of parasites (days 42 and 92 post-infection in Fig. 2e , Extended Data Fig. 2a , Supplementary Information Tables 4 and 5 ). Importantly, mice treated burdens in mouse model of VL as assessed by qPCR (n = 5 mice). b, PK/PD relationship for ten GNF6702 analogues, each administered at several doses; circles, mean liver burdens associated with individual compound regimens (30 regimens in total; n = 5 mice per regimen) relative to vehicle; horizontal dotted line, 90% reduction in the liver L. donovani burden; vertical dotted line, 0.94-fold multiple of the mean free compound plasma concentration/ the L. donovani EC 90 value ratio. c, Post-treatment L. major footpad burdens in the BALB/c mouse model of CL as assessed by qPCR (n = 6 mice); the P values (two-tailed distribution) relate parasite burdens in compoundtreated mice with those from vehicle-treated mice; left inset picture, a representative mouse footpad after treatment with vehicle; right inset picture, a representative mouse footpad after treatment with GNF6702 10 mg kg −1 twice-daily regimen. d, T. cruzi burden in mouse blood (circles), colon (triangles) and heart (diamonds) as assessed by qPCR after 20 days of treatment and four weeks of immunosuppression (n = 8 mice). e, Whole-body in vivo imaging of bioluminescent T. brucei before and after treatment; T. brucei-infected mice were treated by a single intraperitoneal injection of diminazene aceturate (n = 3 mice) or by oral administration of GNF6702 once-daily for 7 days (n = 6 mice); filled symbols show wholebody bioluminescence values for individual mice; several mice from the untreated and diminazene aceturate-treated groups were euthanized between days 28 and 56 due to CNS infection symptoms; background bioluminescence values shown for uninfected mice (grey-filled squares; n = 4) were collected independently from mice aged-matched for day 0 using the same acquisition settings. Red dotted lines in a, c and d show the limit of parasite detection by qPCR; plot symbols below the red dotted line, mice with no detectable parasites; data points below the limit of detection are 'jittered' to show number of animals in a group; thick horizontal lines, means of the treatment groups; RU, relative units (parasite burden relative to the mean burden of the vehicle-treated group). with GNF6702 had no detectable parasites in the brain at termination of the experiment, though parasites were clearly detected in the brains of mice treated with diminazene aceturate (Extended Data Fig. 2b , Supplementary Information Table 6 ). As GNF6702 showed compelling efficacy in four mouse models of kinetoplastid infections: VL, CL, Chagas disease and stage II HAT, we reasoned that mechanistic studies of GNF6702 might identify a pan-kinetoplastid drug target that could inform target-based drug discovery efforts. We attempted to evolve L. donovani strains resistant to GNF3943 and GNF8000 (early analogues from the series, Extended Data Fig. 3 ) through 12 months of parasite culture under drug pressure without success. However, we were able to select two drug-resistant T. cruzi epimastigote isolates, one resistant to GNF3943, and another to GNF8000. Both T. cruzi lines exhibited at least 40-fold lower susceptibility to GNF6702 than wild-type T. cruzi (Extended Data Fig. 4a, b ). Using whole-genome sequencing, we found that the GNF3943-resistant line had a homozygous mutation encoding a substitution of isoleucine for methionine at amino acid 29 in the proteasome β4 subunit (PSMB4 I29M/I29M ) and a heterozygous mutation P82L in dynein heavy chain gene. The GNF8000-resistant line had a heterozygous F24L mutation in PSMB4, and four other heterozygous mutations (Extended Data Table 1 ). We focused our attention on the proteasome as a likely target for the compound series because we found two independent mutations in the PSMB4 gene, and because the proteasome is an essential enzyme in eukaryotic cells. We also note that the Plasmodium falciparum proteasome has recently been the target of promising drug discovery efforts for malaria 26 .
We first asked whether two prototypic inhibitors of mammalian proteasome, bortezomib and MG132, could also block T. cruzi growth. Indeed, both compounds inhibited T. cruzi epimastigote proliferation with sub-micromolar potency. However, in contrast to GNF6702, bortezomib and MG132 inhibited proliferation of the two resistant lines (PSMB4 I29M/I29M , PSMB4 wt/F24L ) with comparable potency to the wildtype parasites. Additionally, the PSMB4 mutant lines were not resistant to nifurtimox, an anti-kinetoplastid drug with an unrelated mechanism of action (Extended Data Fig. 4a, b ). To determine whether the F24L mutation was sufficient to confer resistance to GNF6702, we engineered T. cruzi epimastigote lines that ectopically expressed either wild-type or F24L-mutated PSMB4. Overexpression of wild-type PSMB4 had little effect on the EC 50 value for GNF6702, whereas overexpression of PSMB4 F24L caused a greater than tenfold reduction in GNF6702 potency, but not in that of bortezomib ( Fig. 3a , Extended Data Fig. 4c ). Previously, bortezomib was also shown to inhibit the growth of T. brucei, suggesting that proteasome activity is essential for growth in this parasite as well 27 . To test whether PSMB4 F24L can rescue growth inhibition by GNF6702 in T. brucei, we engineered two parasite strains that ectopically expressed wild-type and F24L-mutated PSMB4, respectively. Similar to T. cruzi, overexpression of PSMB4 F24L in T. brucei conferred a high level of resistance to GNF6702 (~70-fold shift in EC 50 value), while having no effect on parasite susceptibility to bortezomib ( Fig. 3b , Extended Data Fig. 4c ).
We next asked whether GNF6702 could inhibit any of three T. cruzi proteasome proteolytic activities in biochemical assays. As predicted from the T. cruzi genome 28 , mass spectrometry analysis of purified T. cruzi proteasome identified seven alpha and seven beta proteasome subunits, including PSMB4 (Supplementary Tables 7 and 8). Using substrates that are specific for each of the chymotrypsin-like, trypsinlike and caspase-like proteolytic activities, we found that only the chymotrypsin-like activity of the T. cruzi proteasome was inhibited by GNF6702 (IC 50 = 35 nM), while the other two activities were not affected (IC 50 > 10 μM). In contrast, bortezomib inhibited the chymotrypsin-like (IC 50 = 91 nM), the caspase-like (IC 50 = 370 nM) and the trypsin-like (IC 50 = 1.7 μM) activities. We further found that the chymotrypsin-like activity of the PSMB4 I29M T. cruzi proteasome was at least 300-fold less susceptible to GNF6702 (IC 50 > 10 μM) and ~3-fold less susceptible to bortezomib (IC 50 = 0.26 μM), while susceptibility of the other two mutant proteasome proteolytic activities to the two inhibitors were not affected ( Fig. 4a , Extended Data Table 2 ).
We reasoned that if the primary mechanism of parasite growth inhibition by the compound series was through inhibition of the proteasome chymotrypsin-like activity, then the IC 50 values for this proteolytic activity should correlate with EC 50 values for parasite proliferation. Indeed, a tight correlation between the two parameters was observed for L. donovani axenic amastigotes and T. brucei bloodstream form trypomastigotes (r 2 = 0.78 and r 2 = 0.67, respectively) over a 2,000-fold potency range for 317 analogues, thus indicating that inhibition of parasite proteasome activity was driving the anti-parasitic activity of these compounds. We observed a weaker correlation between IC 50 and EC 50 values for intracellular T.cruzi (r 2 = 0.36, P < 0.01), perhaps reflecting more complex cellular pharmacokinetics resulting from compounds having to access T. cruzi parasites within the cytosol of mammalian cells (Fig. 4b , Extended Data Fig. 5 ).
Both resistant T. cruzi lines retained sensitivity to bortezomib, which is a substrate-competitive inhibitor, suggesting that GNF6702 might have an alternative mode of inhibition. A Lineweaver-Burk plot of chymotrypsin-like activity at increasing concentrations of peptide substrate showed that GNF6702 has a non-competitive mode of inhibition clearly distinct from the competitive mechanism described for MG132 and bortezomib 29,30 . We were also able to extend these observations to proteasome from L. donovani (Fig. 4c , Extended Data Table 3 ). We further note that GNF6702 had no measurable activity on the human proteasome ( Fig. 4d , Extended Data Table 2 ). Interestingly, human proteasome β4 subunit has a methionine at the 29th amino acid position, mirroring the I29M mutation in the GNF3943-resistant T. cruzi line (Extended Data Fig. 6a ).
In summary, GNF6702 blocks the chymotrypsin-like activity harboured by the β5 subunit without competing with substrate binding, and mutations in the β4 subunit, which is in direct physical contact with the β5 subunit, confer resistance to this inhibition. Next we used homology modelling of the T. cruzi proteasome to look for evidence of an allosteric inhibitor binding site. In the T. cruzi proteasome model, the F24 and I29 β4 residues are positioned at the interface between the β4 and β5 subunits, on the outer limit of the β5 active site. Adjacent to these two β4 residues and the β5 active site is a plausible binding pocket for GNF6702 (Extended Data Fig. 6b, c ).
Finally, we tested whether GNF6702 can inhibit proteasome activity in intact T. cruzi cells. Cellular proteins entering the proteasome degradation pathway are first tagged with ubiquitin, and proteasome inhibition results in intracellular accumulation of ubiquitylated proteins. Treatment of T. cruzi epimastigotes with GNF6702 led to substantial build-up of ubiquitylated proteins (Extended Data Fig. 7a ) with the half-maximal effect (EC 50 ) achieved at 130 nM compound concentration (Extended Data Fig. 7c ). This EC 50 value correlated well with the half-maximal growth inhibitory concentration of GNF6702 on T. cruzi epimastigotes (EC 50 = 150 nM; Extended Data Fig. 4b ). For comparison, similar experiments with bortezomib yielded comparable inhibitor potencies in the two T. cruzi assays (ubiquitylation EC 50 = 62 nM versus growth inhibition EC 50 = 160 nM; Extended Data Figs 4b and 7c). We did not observe any detectable accumulation of ubiquitylated proteins in mammalian 3T3 cells treated with GNF6702 (Extended Data Fig. 7b , c), further confirming the high selectivity of this compound.
Validation of the parasite proteasome as the target of GNF6702 is supported through several lines of evidence: (i) point mutations in the PSMB4 gene are sufficient to confer resistance to biochemical proteasome inhibition and cellular T. cruzi growth inhibition; (ii) GNF6702 is a selective inhibitor of parasite proteasome activity and does not inhibit the human proteasome, mirroring the selective inhibition of parasite growth over mammalian cell growth; and (iii) potency of GNF6702 and analogues in parasite proteasome assays predict potency in parasite growth-inhibition assays.
In this work we show that in mouse disease models, GNF6702 was able to eradicate parasites from diverse niches that included the cytosol (T. cruzi), phagolysosome (L. donovani, L. major) of infected host cells, and brain (T. brucei). GNF6702 has also good pharmacokinetic properties, and the compound did not show activity in panels of human receptor, enzyme and ion channel assays ( Supplementary Tables  9-11 ). Going forward, GNF6702, or analogues thereof, has potential to yield a new treatment for several kinetoplastid infections and it is currently being evaluated in preclinical toxicity studies. It is unclear if the clinical utility of GNF6702 could extend to the treatment of stage II HAT as GNF6702 was tested in the HAT mouse model only at one high dose (100 mg kg −1 once-daily). We also note that identification of a broadly active pan-kinetoplastid drug might not be feasible (or desirable) as such a drug would need to reach high concentrations in varied tissues/subcellular compartments, and might carry increased toxicity risk. Instead, alternative analogues from this series with different pharmacological profiles might be needed for treatment of different kinetoplastid infections. Nevertheless, there are only scarce resources for drug development in these diseases, and identification of a common target and chemical scaffold with potential across multiple indications provides new hope for improved treatment options for some of the world's poorest people.
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METHODS
No statistical methods were used to predetermine sample size. Ethics statement for animal models. All procedures involving mice were performed in accordance with AAALAC standards or under UK Home Office regulations, and were reviewed and approved in accordance with the Novartis Animal Welfare Policy. Sample size was determined on the basis of the minimum number of animals required for good data distribution and statistics. Blinding was not possible in these experiments but animals were selected randomly for each group. To determine compound growth inhibitory potency on L. donovani axenic amastigotes, 100 nl of serially diluted compounds in DMSO were transferred to the wells of white, solid bottom 384-well plates (Greiner Bio-One) by Echo 555 acoustic liquid handling system (Labcyte). Then, 1 × 10 3 of L. donovani axenic amastigotes in 40 μl of Axenic Amastigote Medium were added to each well, and plates were incubated for 48 h at 37 °C/ 5% CO 2 . Parasite numbers in individual plate wells were determined through quantification of intracellular ATP. The CellTiter-Glo luminescent cell viability reagent (Promega) was added to plate wells, and ATP-dependent luminescence signal was measured on an EnVision MultiLabel Plate Reader (Perkin Elmer). Luminescence values in wells with compounds were divided by the average luminescence value of the plate DMSO controls, and used for calculation of compound EC 50 values as described above.
Axenic amastigote EC 50 values shown in Fig. 4b correspond to means of 2 technical replicates. Isolation and maintenance of Leishmania donovani splenic amastigotes. Female BALB/cJ mice (Envigo) infected with L. donovani MHOM/ET/67/HU3 (ATCC) for 50-80 days were euthanized, and infected spleens were removed and weighed. The weight of an infected spleen ranged from 300 to 600 mg. For comparison, spleens from non-infected age-matched BALB/cJ mice weighed ~100 mg. Infected spleens were washed in Axenic Amastigote Medium (composition described above) and placed into Falcon 50 ml conical centrifuge tubes (Fisher Scientific) containing ice-cold Axenic Amastigote Medium (15 ml per infected spleen). Spleens were homogenized on ice in a Dounce homogenizer and centrifuged at 200g for 15 min at 4 °C to remove tissue debris. Leishmania donovani amastigotes present in the supernatant were pelleted by centrifugation at 1,750g for 15 min at 4 °C and re-suspended either in Axenic Amastigote Medium (when used for in vitro macrophage infections) or in Hanks' Balanced Salt Solution (when used for mouse infections; Hyclone). Suspensions of splenic amastigotes were kept on ice and used for in vitro or in vivo infections within 2-3 h. To propagate L. donovani amastigotes in vivo, 6-7-week-old female BALB/cJ mice were infected with 8 × 10 7 purified splenic amastigotes in 200 μl of Hanks' Balanced Salt Solution by tail vein injection.
Leishmania donovani intra-macrophage amastigote growth-inhibition assay.
In vitro compound potencies on intra-macrophage L. donovani MHOM/ET/67/ HU3 were determined using primary murine peritoneal macrophages infected with L. donovani splenic amastigotes. Primary macrophages were elicited in female BALB/cJ mice for 72 h following the injection of 500 μl of sterile aqueous 2% starch (J. T. Baker) solution into the mouse peritoneal cavity. The protocol used for isolation of peritoneal macrophages was described in detail previously 31 . The isolated macrophages were re-suspended in Macrophage Infection Medium (RPMI-1640 medium supplemented with 2 mM l-glutamine, 10% heat-inactivated fetal bovine serum, 10 mM sodium pyruvate (Hyclone), and 100 IU penicillin/ 100 μg/ml streptomycin), and 50 μl of macrophage suspension (4 × 10 5 macrophages/ml) were added to microscopy-grade, clear-bottom, black 384-well plates (Greiner Bio-One). Following overnight incubation at 37 °C/ 5% CO 2 , plate wells were washed with Macrophage Infection Medium to remove non-adherent cells using ELx405 Select microplate washer (BioTek), and then filled with 40 μl of Macrophage Infection Medium. Leishmania donovani HU3 splenic amastigotes isolated from infected spleens were re-suspended in Macrophage Infection Medium at a concentration of 6 × 10 7 cells/ml, and 10 μl of the suspension were added to assay plate wells containing adherent macrophages. After a 24-h infection period at 37 °C/ 5% CO 2 , plate wells were washed with Macrophage Infection Medium to remove residual extracellular parasites and re-filled with 50 μl of the medium. Leishmania donovani-infected macrophages were subsequently treated with DMSO-dissolved compounds (0.5% final DMSO concentration in the assay medium) in dose response for 120 h at 37 °C/ 5% CO 2 . Next, treated macrophages were washed with the phosphate-buffered saline buffer (PBS; Sigma-Aldrich) supplemented with 0.5 mM magnesium chloride (Sigma-Aldrich) and 0.5 mM calcium chloride (Sigma-Aldrich), fixed with 0.4% paraformaldehyde (Sigma-Aldrich) in PBS, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) in PBS, and stained with SYBR Green I nucleic acid stain (Invitrogen, 1:100,000 dilution in PBS) overnight at 4 °C. Image collection and enumeration of macrophage cells and intracellular L. donovani amastigotes was performed using the OPERA QEHS automated confocal microscope system equipped with 20× water immersion objective (Evotec Technologies) and the OPERA Acapella software (Evotec Technologies) as described previously 32 .
All reported intra-macrophage L. donovani EC 50 values were calculated from at least 3 technical replicates (n = 3 or n = 4; specified in relevant figure captions). Trypanosoma brucei growth inhibition assay. Bloodstream form Trypanosoma brucei Lister 427 parasites were continuously passaged in HMI-9 medium formulated from IMDM medium (Invitrogen), 10% heat-inactivated fetal bovine serum, 10% Serum Plus medium supplement (SAFC Biosciences), 1 mM hypoxanthine (Sigma-Aldrich), 50 μM bathocuproine disulfonic acid (Sigma-Aldrich), 1.5 mM cysteine (Sigma-Aldrich), 1 mM pyruvic acid (Sigma-Aldrich), 39 μg/ml thymidine (Sigma-Aldrich), and 14 μl/lβ-mercapthoethanol (Sigma-Aldrich); all concentrations of added components refer to those in complete HMI-9 medium. The parasites were cultured in 10 ml of HMI-9 medium in T75 CELL-STAR tissue culture flasks at 37 °C/ 5% CO 2 .
To determine compound growth inhibitory potency on T. brucei bloodstream form parasites, 100 nl of serially diluted compounds in DMSO were transferred to the wells of white, solid bottom 384-well plates (Greiner Bio-One) by Echo 555 acoustic liquid handling system. Then, 5 × 10 3 of T. brucei parasites in 40 μl of HMI-9 medium were added to each well, and the plates were incubated for 48 h at 37 °C/ 5% CO 2 . Parasite numbers in individual plate wells were determined through quantification of intracellular ATP amount. The CellTiter-Glo luminescent cell viability reagent was added to plate wells, and ATP-dependent luminescence signal was measured on an EnVision MultiLabel Plate Reader. Luminescence values in wells with compounds were divided by the average luminescence value of the plate DMSO controls, and used for calculation of compound EC 50 values as described above.
Trypanosoma brucei EC 50 values shown in Fig. 1 and Extended Data Fig. 3 correspond to means of 4 technical replicates. Trypanosoma cruzi amastigote growth-inhibition assay. NIH 3T3 fibroblast cells (ATCC) were maintained in RPMI-1640 medium (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum and 100 IU penicillin/ 100 μg/ml streptomycin at 37 °C/ 5% CO 2 . Trypanosoma cruzi Tulahuen parasites constitutively expressing Escherichia coli β-galactosidase 33 were maintained in tissue culture as an infection in NIH 3T3 fibroblast cells. Briefly, 2 × 10 7 T. cruzi trypomastigotes were used to infect 6 × 10 5 NIH 3T3 cells growing in T75 CELL-STAR tissue culture flasks and cultured at 37 °C/ 5% CO 2 until proliferating intracellular parasites lysed host 3T3 cells and were released into the culture medium (typically 6-7 days). During the infection, the tissue culture medium was changed every two days. Number of T. cruzi trypomastigotes present in 1 ml of medium was determined using a haemocytometer.
To determine compound potency on intracellular T. cruzi amastigotes, NIH 3T3 cells were re-suspended in phenol red-free RPMI-1640 medium containing 3% heat-inactivated fetal bovine serum and 100 IU penicillin/ 100 μg/ml streptomycin, seeded at 1,000 cells/ well (40 μl) in white, clear bottom 384-well plates (Greiner Bio-One), and incubated overnight at 37 °C/ 5% CO 2 . The following day, 100 nl of each compound in DMSO were transferred to individual plate wells by Echo 555 acoustic liquid handling system. After one hour incubation, 1 × 10 6 of tissue culture-derived T.cruzi trypomastigotes, in 10 μl of phenol red-free RPMI-1640 medium supplemented with 3% heat-inactivated fetal bovine serum and 100 IU penicillin/ 100 μg/ml streptomycin were added to each well. Plates were then incubated for 6 days at 37 °C/ 5% CO 2 . Intracellular T. cruzi parasites were quantified by measuring the activity of parasite-expressed βgalactosidase. Ten microlitres of a chromogenic β-galactosidase substrate solution (0.6 mM chlorophenol red-β-D-galactopyranoside/ 0.6% NP-40 in PBS; both reagents from Calbiochem) were added to each well and incubated for 2 h at room temperature. After incubation, absorption was measured at 570 nM on SpectraMax M2 plate reader (Molecular Devices). Measured absorbance values in wells with compounds were divided by the average absorbance value of the plate DMSO controls, and used for calculation of compound EC 50 values as described above.
Trypanosoma cruzi amastigote EC 50 values shown in Fig. 1 and Extended Data Fig. 3 correspond to means of 4 technical replicates. Trypanosoma cruzi epimastigote proliferation assay. Trypanosoma cruzi CL epimastigotes were continuously passaged in LIT medium containing 9 g/l liver infusion broth (Difco), 5 g/l bacto tryptose (Difco), 1 g/l sodium chloride, 8 g/l dibasic sodium phosphate (Sigma-Aldrich), 0.4 g/l potassium chloride (Sigma-Aldrich), 1 g/l d-glucose, 10% heat-inactivated fetal bovine serum and 10 ng/ml of hemin (Sigma-Aldrich). The medium was adjusted to pH = 7.2 with 6 M hydrochloric acid. The parasites were cultured in 10 ml of LIT medium in T75 CELL-STAR tissue culture flasks at 27 °C.
To determine compound growth inhibitory potency on T. cruzi epimastigotes, 100 nl of serially diluted compounds in DMSO were transferred to the wells of white, solid bottom 384-well plates (Greiner Bio-One) by an Echo 555 acoustic liquid handling system. Then, 5 × 10 3 of T. cruzi epimastigotes in 40 μl of LIT medium were added to each well, and the plates were incubated for 7 days at 27 °C. Parasite numbers in individual plate wells were determined through quantification of intracellular ATP amount. The CellTiter-Glo luminescent cell viability reagent was added to plate wells, and ATP-dependent luminescence signal was measured on an EnVision MultiLabel Plate Reader. Luminescence values in wells with compounds were divided by the average luminescence value of the plate DMSO controls, and used for calculation of compound EC 50 values as described above.
Trypanosoma cruzi epimastigote EC 50 values shown in Extended Data Fig. 4 correspond to means of 3 technical replicates. Mouse fibroblast NIH 3T3 growth-inhibition assay. NIH 3T3 fibroblast cells were maintained in RPMI-1640 medium with glutamine (Life Technologies) supplemented with 5% heat-inactivated fetal bovine serum and 100 IU penicillin/ 100 μg/ml streptomycin (3T3 medium) at 37 °C/ 5% CO 2 . NIH 3T3 fibroblast cells were purchased from ATCC. We did not perform cell line authentication and did not test the cells for mycoplasma contamination. This cell line is not listed in the database of commonly misidentified cell lines maintained by ICLAC and NCBI Biosample.
To determine compound potency, NIH 3T3 cells re-suspended in 3T3 medium were seeded at 1,000 cells/well (50 μl) in white 384-well plates (Greiner Bio-One) and incubated overnight at 37 °C/ 5% CO 2 . The following day, 100 nl of each compound in DMSO were transferred to individual plate wells by Echo 555 acoustic liquid handling system and plates were incubated for five days at 37 °C/ 5% CO 2 . Cell numbers in individual plate wells were determined through quantification of intracellular ATP amount. The CellTiter-Glo luminescent cell viability reagent was added to plate wells, and ATP-dependent luminescence signal was measured on an EnVision MultiLabel Plate Reader. Luminescence values in wells with compounds were divided by the average luminescence value of the plate DMSO controls, and used for calculation of compound CC 50 values as described above.
NIH 3T3 CC 50 values shown in Fig. 1 and Extended Data Fig. 3 correspond to means of 4 technical replicates. Primary macrophage cytotoxicity assay. Primary macrophage cell viability was determined on mouse peritoneal macrophages infected with L. donovani and was expressed as the ratio of the number of macrophage cells in wells treated with a compound to those in wells treated with DMSO. The number of macrophage cells in wells was determined by high content microscopy as described previously 32 .
All reported macrophage CC 50 values were calculated from 4 technical replicates (n = 4; also specified in Fig. 1 and Extended Data Fig. 3 captions) . Selection of GNF3943-and GNF8000-resistant T. cruzi mutants. Trypanosoma cruzi epimastigotes cultures resistant to GNF3943 and GNF8000 were generated using a methodology described previously 32 . Briefly, epimastigotes were initially cultured in the presence of compound concentration equivalent to its EC 20 value (GNF3943 EC 20 = 1.5 μM and GNF8000 EC 20 = 0.2 μM in 0.2% DMSO) or 0.2% DMSO (control). Once a week, parasites were counted and growth rates were determined. If the parasite cultures exhibited a reduced growth rate compared to 0.2% DMSO-treated parasites, epimastigotes were cultured at the same compound concentration. Once the growth rates matched that of the control epimastigote culture (0.2% DMSO), parasites were transferred into medium containing twofold higher compound concentration. The process was repeated until substantial resistance was achieved (~10-to 20-fold increase in corresponding EC 50 value).
The time required for generation of cultures with such a level of resistance was approximately five months. Resistant clones were isolated via cloning by limiting dilution, and two independent clones were analysed by whole-genome sequencing. T. cruzi whole-genome sequencing. Chromosomal DNA isolation from GNF3943-and GNF8000-resistant T. cruzi clones, whole-genome sequencing and sequence analysis were performed as described previously 32 . Sequencing reads were aligned to the T. cruzi CL Brenner genome 34 . Generation of T. cruzi strains ectopically expressing proteasome β4 subunit variants. PSMB4 TcCLB503891.100 was amplified from T. cruzi CL Brenner genomic DNA using KOD Hot Start DNA Polymerase (EMD Millipore), and sense (5′-AAAGCGGCCGCATGTCGGAGACAACCATTG-3′) and antisense (5′-CCATGATCTTGATGTAATATAAGGCATTCAGCCCTGCTG-3′) primers. The PSMB4 F24L gene was generated from the wild-type PSMB4 construct by site-directed mutagenesis using mutagenic sense (5′-CAGCAGGGCTGAATGC CTTATATTACATCAAGATCATGG-3′) and antisense (5′-CCATGATCTTGATG TAATATAAGGCATTCAGCCCTGCTG-3′) primers and QuikChange II Site-Directed Mutagenesis Kit (Stratagene). The sequences of the wild-type and mutant PSMB4 genes were verified by sequencing and both gene versions were subcloned into the T. cruzi expression vector pTcIndex1 under control of a T7 promoter 35 . Trypanosoma cruzi CL Brenner epimastigotes were first transfected as described previously 36 with the pLEW13 plasmid 37 harbouring a tetracycline-inducible T7 RNA polymerase gene. Transfected epimastigotes were selected in medium supplemented with neomycin (G418) at 500 μg/ml, and then transfected a second time with either pTcIndex1-PSMB4 wt or pTcIndex1-PSMB4 F24L plasmid. Doubletransfected epimastigotes were selected in the presence of 500 μg/ml of G418 (Sigma-Aldrich) and 500 μg/ml of hygromycin (Sigma-Aldrich). Susceptibility of double transfected epimastigote cell lines to compounds was assessed using induced (+5 mg/ml of tetracycline) and non-induced parasite cultures after five days of compound treatment. Parasite viability was determined with AlamarBlue (ThermoFisher Scientific).
Reported EC 50 values for T. cruzi epimastigotes ectopically expressing PSMB4 proteins were calculated from 3 technical replicates (n = 3; also specified in the Fig. 3a caption) . Generation of T. brucei strains ectopically expressing proteasome β4 subunit variants. PSMB4 (Tb927.10.4710) was amplified from T. brucei Lister 427 genomic DNA using PCR SuperMix High Fidelity (Invitrogen), sense (5′-GCAAGCTTATGGCAGAGACGACTATCGG-3′) and antisense (5′-GCGGATCCCTAGCTTACAGATTGCACTC-3′) primers. The PSMB4 F24L gene was generated from the wild-type PSMB4 construct by site-directed mutagenesis using mutagenic sense (5′-GCTGCGGGGTTAAATGCGTTATACTAC ATTAAGATAACGG-3′), antisense (5′-CCGTTATCTTAATGTAGTATAACG CATTTAACCCCGCAGC-3′) primers and QuikChange II Site-Directed Mutagenesis Kit (Stratagene). The sequences of the wild-type and mutant PSMB4 genes were verified by sequencing and both gene versions were cloned into the T. brucei expression vector pHD1034 under control of a ribosomal RNA promoter. Transfected T. brucei Lister 427 cells were selected in medium supplemented with puromycin at 1 μg/ml. Susceptibility of transfected T. brucei cell lines to compounds was assessed after 2 days of compound treatment. Parasite viability was determined with CellTiter-Glo.
Reported EC 50 values for T. brucei parasites ectopically expressing PSMB4 proteins were calculated from 3 technical replicates (n = 3; also specified in the Fig. 3b caption) . Purification of parasite 20S proteasomes. Trypanosoma cruzi CL epimastigotes, L. donovani MHOM/SD/62/1 S-CL2D axenic amastigotes and T. brucei Lister 427 bloodstream form trypomastigotes were grown to log phase and harvested by centrifugation. The corresponding cell pellets were stored at −80 °C until further use. Prior to purification, 10 g of cell pellets were thawed, re-suspended in lysis buffer (50 mM Tris-HCl pH = 7.5, 1 mM TCEP, 5 mM EDTA, and 10 μM E-64), and lysed by passing cell suspension three times through a needle (22 gauge) and by subsequent three freeze/thaw cycles. The lysate was first cleared of cellular debris by two centrifugation steps (15,000g at 4 °C for 15 min followed by 40,000g at 4 °C for 60 min) and then fractionated through ammonium sulphate precipitation. The protein fraction precipitated between 45% and 65% of ammonium sulphate saturation was re-suspended in 25 mM Tris-HCl pH = 7.5, 1 mM TCEP buffer, and dialysed overnight at 4 °C against the same buffer. Proteasomes were further purified by anion exchange chromatography (Resource Q column, GE Healthcare Life Sciences) and size-exclusion chromatography (Superose 6 column, GE Healthcare Life Sciences) as described elsewhere 38 . Active fractions from the latter purification step were pooled and used in proteasome biochemical assays.
Subunit composition analysis of purified T. cruzi 20S proteasome by LC-MS/MS.
Purified T. cruzi proteasome sample was buffer-exchanged and concentrated into 100 mM trimethylamine bicarbonate-HCl pH = 8.0, 150 mM NaCl buffer LETTER RESEARCH using a 10 kDa molecular weight cut-off micro-concentrator (Milipore Amicon Ultra). The resulting proteasome sample (200 μl, 1 mg/ml) was mixed with 5 μl of a TMTsixplex reagent (Pierce). After 60 s incubation to label primary amines, the reaction was stopped by adding 25 μl of 5% hydroxylamine. The labelled sample was run on 4-20% Bis-Tris PAGE gel (Invitrogen) to separate polypeptides. The gel was stained with eStain 2.0 (GenScript). Stained protein bands were cut out and in-gel-digested separately with elastase (Promega) and asparaginase (Roche). Peptides generated by the digestions were resolved by HPLC using a vented column setup with a 2 cm Poros 10 R2 (Life Technologies, Carlsbad, CA) self-packed pre-column, and a PepMap Easy-Spray C18 analytical column (15 cm × 75 μm ID, Thermo Scientific). Resin-bound proteolytic fragments were eluted with 2 to 40% acetonitrile / 0.1% formic acid operated at 300 nl/min for 120 min. Spectra of eluted peptide species were determined by a column-coupled Q Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Scientific). Proteome Discoverer v1.4 software (Thermo Scientific) was used to search the T.cruzi genome 28 with identified spectra for presence of 20S proteasome subunits (Supplementary Table 7 ). Search parameters included fixed carbamidomethyl modification of cysteine, and variable oxidation of methionine, deamidation of asparagine, pyroglu of N-terminal glutamine, and TMT(6-plex) modification of lysine residues. Measuring proteasome proteolytic activities. The activity of purified parasite and human 20S proteasomes was monitored by measuring cleavage of various rhodamine-labelled fluorogenic substrates. Purified 20S proteasomes were diluted in proteasome assay buffer (25 mM Tris-HCl pH 7.5, 1 mM dithiothreitol (Sigma-Aldrich), 10 mM sodium chloride, 25 mM potassium chloride, 1 mM magnesium chloride, 0.05% (w/v) CHAPS (Sigma-Aldrich) and 0.9% DMSO) at a final concentration of 162 nM (parasite proteasomes) or 25 nM (human proteasome), and pre-incubated with compound (40 nl; 0.2% final DMSO concentration) for 1 h. Next, the following substrates (Biosynthan GmbH) were added at 3 μM final concentration to monitor specific proteolytic activities (Suc-LLVY-Rh110-dPro: chymotrypsin-like activity; Ac-RLR-Rh110-dPro: trypsin-like activity; Ac-GPLD-Rh110-dPro: caspase-like activity). The reaction was allowed to proceed for two hours at room temperature and fluorescence as a measure of purified 20S proteasome activity was monitored using the EnVision plate reader (excitation at 485 nm/emission at 535 nm). K m and K i values were calculated using GraphPad Prism (GraphPad Software) 'non-competitive enzyme inhibition' function.
Data shown in Fig. 4a, c, d and Extended Data Table 3 represent means of 3 technical replicates (n = 3). Data shown in Fig. 4b and Extended Data Fig. 5 represent means of 2 technical replicates (n = 2). Monitoring accumulation of ubiquitylated proteins in intact cells. Growing T. cruzi CL epimastigotes were seeded into 24-well tissue culture plate (1 × 10 7 cells per well) in LIT medium and treated for 2-12 h with DMSO (0.2%) or various concentrations of bortezomib and GNF6702 at 27 °C. Following the treatment, parasites were collected by centrifugation (3,500g for 6 min) and washed twice with phosphate-buffered saline (PBS). Epimastigotes were lysed by resuspending washed cells in a buffer containing 50 mM Tris-HCl pH = 7.4, 150 mM sodium chloride, 1% CHAPS, 20 μM E-64 (Sigma-Aldrich), 10 mM EDTA(Sigma-Aldrich), 5 mM N-ethylmaleimide(Sigma-Aldrich), 1 mM phenylmethylsulfonyl fluoride (Sigma-Aldrich), 10 μg/ml leupeptin (Sigma-Aldrich), 10 μg/ml aprotinin (Sigma-Aldrich), and incubating the suspension on ice for 20 min. Cell lysates were cleared by centrifugation at 21,000g for 30 min at 4 °C.
For 3T3 cells, 2 × 10 5 cells/well were seeded into 24-well tissue culture plates in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, and incubated overnight at 37 °C to allow cells to attach. Attached cells were treated for 2 h with DMSO (0.25%) or various concentrations of bortezomib and GNF6702. Treated cells were washed twice with PBS and then lysed by incubating cells in modified RIPA buffer (50 mM Tris-HCl pH = 7.4, 1% Triton X-100, 0.2% sodium dodecylsulfate, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 5 μg/ml aprotinin, 5 μg/ml leupeptin) for 30 min at 4 °C. Cell lysates were cleared by centrifugation at 21,000g for 30 min at 4 °C.
Protein concentration in cell extracts was determined with BCA assay (ThermoFisher), and 10 μg of cell extracts were loaded on NuPAGE Novex 4-12% Bis-Tris gel (Invitrogen). After electrophoresis, resolved proteins were transferred to nitrocellulose membrane. Ubiquitylated proteins were detected with polyclonal anti-ubiquitin primary antibody (Proteintech, catalogue number 10201-2-AP) and rabbit anti-mouse IgG-peroxidase antibody (Sigma-Aldrich, catalogue number A0545), and then imaged using ECL Prime Western Blotting Detection Reagent (Amersham) on Chemidoc XR+ imaging system (BioRad). Collected western blot images were quantified using Image Lab software (BioRad). Briefly, rectangles of identical size and shape were drawn around each blot lane to include inside the shape all ubiquitylated protein bands within 17-198 kDa molecular mass range. Next, integrated signal intensities within the rectangles (reported by the Image Lab software) were used for calculation of EC 50 values. Three technical replicate experiments (n = 3) for each different dose response experiment (GNF6702 on T. cruzi epimastigotes; GNF6702 on 3T3 cells; bortezomib on T. cruzi epimastigotes; bortezomib on 3T3 cells) were performed. Trypanosoma cruzi proteasome modelling studies. The homology model of T. cruzi 20S proteasome was built using 'Prime' protein structure prediction program (Schrödinger) and X-ray structure of bovine 20S proteasome (PDB accession code 1IRU) 39 as the template. The model was subjected to restrained minimization to relieve inter-chain clashes. 'SiteMap' program (Schrödinger) was used to identify pockets on a protein surface suitable for small molecule binding. Flexible ligand docking was performed using 'Glide 5.8' (Schrödinger). The grid box was centred in a middle of the identified pocket and extended by 10 Å, with outer box extending an additional 20 Å. The ligand was docked using the standard precision (SP) algorithm and scored using 'GlideScore' (Schrödinger). The GNF6702 GlideScore is equal to −8.5. Receptor, enzyme and ion channel assays. GNF6702 profiling was performed at 10 μM concentration in a selectivity panel at Eurofins (www.eurofinspanlabs.com/ Catalog/AssayCatalog/AssayCatalog.aspx). Listed values correspond to the assay readout values expressed relative to the DMSO control. To determine inhibition of a subset of human tyrosine kinases by GNF6702, the inhibitor was profiled on a panel of Ba/F3 cell lines expressing individual Tel-activated kinases as described previously 40 . All assays were performed as single technical repeats. Determination of GNF6702 thermodynamic solubility. The solubility of GNF6702 was assessed in a high throughput thermodynamic solubility assay as described previously 41 . First, 25 μl of GNF6702 DMSO solutions were transferred to individual wells of a 96-well plate. DMSO was evaporated and 250 μl of 67 mM potassium phosphate buffer pH 6.8 were added to yield projected final compound concentrations from 1 μM to 100 μM. The plate was sealed to prevent solvent loss and shaken for 24 h at room temperature. The plate was then filtered to remove non-dissolved material. Concentration of GNF6702 in individual plate wells was determined by measuring solution UV absorbance with reference to a GNF6702 calibration curve. Determination of GNF6702 permeability in Caco-2 assay. A 96-Multiwell Insert System (BD Biosciences) was used for the Caco-2 cell culture and permeability assay as described previously 42 . Caco-2 cells were seeded onto insert wells at a density of 1.48 × 10 5 cells per ml and allowed to grow for 19-23 days before assays. To measure both absorptive (apical to basolateral (A-B)) and secretory (basolateral to apical (B-A)) compound transport, a solution of GNF6702 at 10 μM concentration in 0.5% DMSO were added to donor wells. The plate was incubated at 37 °C for 2 h, with samples taken at the beginning and end of the incubation from both donor and acceptor wells. The concentration of GNF6702 was determined by LC-MS/MS. Apparent drug permeability (P app ) was calculated using the following equation:
where dQ/dt is the total amount of a test compound transported to the acceptor chamber per unit of time (nmol/s), A is the surface area of the transport membrane (0.0804 cm 2 ), C in is the initial compound concentration in the donor chamber (10 μM), and P app is expressed as cm/s. Determination of human CYP450 inhibition by GNF6702. Extent of inhibition of major human CYP450 isoforms 2C9, 2D6 and 3A4 by GNF6702 was determined using pooled human liver microsomes and the known specific substrates of various CYP450 isoforms: diclofenac (5 μM), bufuralol (5 μM), midazolam (5 μM), and testosterone (50 μM). Probe substrate concentrations were used at concentrations equal to their reported K m values. The CYP450 inhibition assays with probe substrates diclofenac (2C9) or midazolam (3A4) were incubated at 37 °C for 5 to 10 min using a microsomal protein concentration of 0.05 mg/ml. Probe substrates bufuralol (2D6) and testosterone (3A4) were incubated at 37 °C for 20 min using microsomal concentration 0.5 mg/ml. The test concentrations of GNF6702 ranged from 0.5 to 25 μM in the presence of 1% DMSO. The reactions were initiated by adding NADPH (1 mM final concentration; Sigma-Aldrich) after a 5-min pre incubation. Incubations were terminated by the addition of 300 μl of acetonitrile to 100 μl of a sample. No detectable cytochrome P450 inhibition was observed. Extent of CYP450 isoform inhibition was determined by quantifying residual concentrations of individual CYP450 substrate probes at the end of reactions by LC-MS/MS. Determination of GNF6702 in vitro metabolic stability. The intrinsic metabolic stability of GNF6702 was determined in mouse and human liver microsomes using the compound depletion approach and LC-MS/MS quantification. The assay measured the rate and extent of metabolism of GNF6702 by measuring the disappearance of the compound. The assay determined GNF6702 in vitro half-life LETTER RESEARCH sterile water was administered by i.p. injection (n = 3). A group of untreated mice (n = 3) was included as controls.
Mice were monitored weekly for parasitemia from day 21 post-infection. Trypanosoma brucei was quantified in blood samples from the tail vein by microscopy, and in vivo bioluminescence imaging of infected mice was performed before treatment on day 21 post-infection and in weeks following the treatment (day 28, 35, 42, 56, 63, 72, 84 , 92 post-infection). Imaging on groups of three mice was performed 10 min after i.p. injection of 150 mg d-luciferin (Promega)/kg body weight (in PBS) using an IVIS Spectrum (Perkin Elmer) as described previously 25 . A group of uninfected mice (aged-matched for day 0 time point; n = 4) were imaged using the same acquisition settings to show the background bioluminescence ( Fig. 2e , grey-filled squares) in the absence of luciferase-expressing T. brucei after day 92 of the experiment. Untreated and diminazene-treated mice were euthanized on days 32 and 35, and day 42, respectively, due to high parasitemia or the development of symptoms related to CNS infection. GNF6702treated mice were euthanized on day 92. No parasitemia or clinical symptoms were observed at this point. At the specified endpoints mice were sacrificed by cervical dislocation, after which whole brains were removed and imaged ex vivo within 10 min after administration of 100 μl of d-luciferin onto the brain surface. Data analysis for bioluminescence imaging was performed using Living Image Software (Perkin Elmer). The same rectangular region of interest (ROI) covering the mouse body was used for each whole-body image to show the bioluminescence in total flux (photons per second) within that region. Image panels of whole mouse bodies are composites of the original images with areas outside the ROI cropped out to save space. For ex vivo brain images the same oval shaped ROI was used to display the bioluminescence detected for each mouse brain at the respective endpoints. Chemical synthesis. The detailed procedures for chemical synthesis are presented in Supplementary Information.
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Extended Data Figure 1 | Pharmacokinetic profile of GNF6702 in mouse. a, Time profiles of mean free plasma concentration of GNF6702 in mouse model of visceral leishmaniasis; free GNF6702 concentration values were predicted from measured total plasma concentration values collected on day 1 and day 8 of treatment. Dashed blue lines correspond to intra-macrophage L. donovani EC 50 of 18 ± 1.8 nM and EC 99 of 42 ± 5.6 nM. Circles, means ± s.d.; n = 3 mice for treatment day 1; n = 5 mice for treatment day 8; fraction unbound in mouse plasma = 0.063. For data points lacking error bars, standard deviations are smaller than circles representing means. b, Time course of total GNF6702 concentration in mouse plasma and brain after single oral dose (20 mg kg −1 ); n = 2 mice per time point; circles, measured values; rectangles, means.
Extended Data Figure 2 | GNF6702 clears parasites from mice infected with T. brucei. a, In vivo quantification of bioluminescent T. brucei in infected mice before and after treatment. i.p., intraperitoneal; day 21, start of treatment; day 28, 24 h after last GNF6702 dose; day 42, evaluation of early parasite recrudescence in mice treated with diminazene aceturate (n = 3); day 42 and 92, absence of parasite recrudescence in mice treated with GNF6702 (n = 6). Images from uninfected mice (3 mice of 4 are shown) aged-matched for day 0 were collected independently using the same acquisition settings. Parasitemia (blue font) and whole mouse total flux (black font) values of each animal are shown above the image; N.D., not detectable. Within each group the mouse numbers in yellow (top left in each image) refer to the same mouse imaged throughout. Complete sets of parasitemia and whole mouse total flux values collected on individual mice throughout the experiment are listed in Supplementary  Tables 4 and 5 . b, Brains from mice shown in a were soaked in luciferin and imaged for presence of bioluminescent T. brucei at the indicated time points. For three diminazene-treated mice, two images of each brain are shown, one at a lower sensitivity (left) and the other at a high signal intensity scale.
